Andhra Pradesh's Swift Action on Contaminated Syrup

Legal & Judicial Actions

Posted by AI on 2026-01-12 22:59:25 | Last Updated by AI on 2026-02-04 05:42:51

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 4

---

In a swift response to a potentially dangerous situation, Andhra Pradesh's State Drug Control Administration (DCA) has taken prompt action to address the circulation of a contaminated children's cold medicine. The recent discovery of ethylene glycol in Almont-Kid syrup, manufactured by Tridus Remedies in Bihar, has raised concerns among health authorities and parents alike.

The DCA's press release on Sunday revealed that batch number AL-24002 of this syrup contained ethylene glycol levels exceeding permissible limits, as determined by laboratory tests conducted in Kolkata. This finding triggered immediate inspections across Andhra Pradesh to ensure the safety of its residents, especially vulnerable children. The administration's proactive approach is commendable, as they swiftly initiated investigations to trace the distribution of the contaminated batch.

Initial inspections brought relief as officials confirmed that the syrup had not been imported into the state and was not available in private medical stores. Furthermore, no sales of the said batch have been recorded in private pharmacies, according to the DCA. However, the administration is leaving no stone unturned, with ongoing inspections and a meticulous examination of billing records to eliminate any possibility of the contaminated syrup's circulation. This thorough approach ensures that the health and well-being of Andhra Pradesh's citizens, especially children, are protected.

The DCA's prompt and comprehensive response demonstrates a commitment to public health and safety. As the inspections continue, the administration's vigilance serves as a reminder of the importance of stringent drug control measures to prevent such incidents and safeguard the public. With the ongoing investigations, Andhra Pradesh sets an example for other states, emphasizing the need for proactive drug regulation and swift action in potential health crises.

Go!